Talquetamab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Talquetamab（JNJ-64407564）是一种人源化的双特异性抗体，可与 GPRC5D(G 蛋白偶联受体家族C5组成员 D) 和 CD3 结合，通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab（JNJ-64407564）具有抗肿瘤活性。

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

——

Animal Model:Female NSG mice with H929 cells Dosage:0.1-10 μg (0.005 mg/kg) Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10 Result:Completely blocked tumor formation at 1 μg and 10 μg doses. Animal Model:Female NSG mice with human MM cells Dosage:0.1-50 μg (0.005 mg/kg) Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36 Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

2226212-40-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years